• Veru received a USPTO notice of allowance for a U.S. patent application covering enobosarm use with semaglutide for “quality” weight loss.
• Claims cover dosing regimens during semaglutide therapy, add-on use, or enobosarm monotherapy following semaglutide discontinuation.
• Patent term would run to at least Oct. 3, 2044 if issued, before any term adjustments or extensions.
• Veru is studying enobosarm with semaglutide in older obesity patients; Phase 2b PLATEAU interim DXA analysis is expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040830PRIMZONEFULLFEED9802637) on August 04, 2026, and is solely responsible for the information contained therein.